All In Biotech

Drug Trial Radar · NCT01139749

Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea

Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea.

Last checked: Nov 20, 2026Latest source record: Oct 12, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 2011

Primary completion

Jul 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Federal University of São PauloAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Oral isotretinoin is the gold standard drug to treat moderate to severe acne. Other indications like seborrhea, seborrheic dermatitis have been suggested. There is risk of reversible mucocutaneous side effects, as well as alterations in lipid profile and transaminases. The major problem is teratogenicity which demands pregnancy control from treatment beginning to one month after treatment end. Seborrhea and seborrheic dermatitis are chronic conditions characterized by oily skin, hair and scalp, erythema, desquamation and negative impact on quality of life. This will be an interventional, therapeutic and quality of life randomized, comparative (parallel groups), blinded evaluation clinical trial, comprising 50 men and women, aged 18 to 40. Treatment with low-dose oral isotretinoin will be compared to topical anti-seborrheic products to evaluate the reduction of sebaceous secretion and colonization of affected areas by yeasts of Malassezia gender. Efficacy will be evaluated by clinical parameters, as well as by sebum secretion measure and application of quality of life questionnaires. Safety will be evaluated by skin hydration measure, side effects report and observation. For subjects using oral isotretinoin blood counting, transaminases, lipid profile and pregnancy test will be requested as selection criteria, on days 30 and 180. Data will be submitted to statistical analysis.

Conditions

  • Seborrhea
  • Seborrheic Dermatitis
  • Quality of Life

Interventions

  • oral isotretinoinDrug

    capsules of 20 mg a day, every other day, for six months

  • salicylic acid and ciclopirox olamineDrug

    Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sebum secretion rateTime frame: day 0
  2. sebum secretion rateTime frame: day 180

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Federal University of Sao Paulo - Dermatology Department - Cosmetic Dermatology Unit

    São Paulo, São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.